197 related articles for article (PubMed ID: 6525601)
21. Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project.
Smalley R; Gams R
Cancer Treat Rep; 1983 Nov; 67(11):1039-40. PubMed ID: 6640553
[No Abstract] [Full Text] [Related]
22. Potential cardiotoxicity with mitoxantrone.
Schell FC; Yap HY; Blumenschein G; Valdivieso M; Bodey G
Cancer Treat Rep; 1982 Aug; 66(8):1641-3. PubMed ID: 7105054
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P
Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363
[No Abstract] [Full Text] [Related]
24. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.
Williams SD; Birch R; Velez-Garcia E; Gams R
Invest New Drugs; 1985; 3(3):311-3. PubMed ID: 4066226
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Evans WK; Raghavan D; Desmeules MJ; Murray NR; Stuart-Harris R; Wilson KS
Cancer Treat Rep; 1986 Aug; 70(8):1029-30. PubMed ID: 3731150
[No Abstract] [Full Text] [Related]
27. Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
Takita H; Brugarolas A; Mittelman A; Vincent R
Cancer Chemother Rep 3; 1973 Mar; 4(2):257-9. PubMed ID: 4125743
[No Abstract] [Full Text] [Related]
28. Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study.
Levin M; Pandya KJ; Khandekar JD; Horton J; Glick JH; Bennett JM; Muggia FM; Falkson G
Cancer Treat Rep; 1984 Dec; 68(12):1511-2. PubMed ID: 6509455
[No Abstract] [Full Text] [Related]
29. Initial therapeutic trial of new drugs in lung cancer.
Selawry OS
Cancer Chemother Rep 3; 1973 Mar; 4(2):215-25. PubMed ID: 4729325
[No Abstract] [Full Text] [Related]
30. Phase II study of mitoxantrone in patients with non-small cell lung cancer.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Hoshi A
Jpn J Clin Oncol; 1986 Jun; 16(2):147-51. PubMed ID: 3735704
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapeutic studies in bronchogenic carcinoma by the Austrian study group.
Karrer K; Pridun N; Zwintz E
Cancer Chemother Rep 3; 1973 Mar; 4(2):207-13. PubMed ID: 4729324
[No Abstract] [Full Text] [Related]
32. [Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
Rebattu P; Coudert B; Schneider M; Ouabdesselam R; Lentz M; Hanauske A; Chevallierdagger B; Fumoleau P; Chollet P
Rev Pneumol Clin; 2000 Jun; 56(3):200-3. PubMed ID: 10880946
[TBL] [Abstract][Full Text] [Related]
33. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
DeSimone PA; Gams R; Bartolucci A
Am J Clin Oncol; 1984 Oct; 7(5):517-22. PubMed ID: 6507372
[TBL] [Abstract][Full Text] [Related]
34. [Phase II study of mitoxantrone for hematologic malignancies].
Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of mitoxantrone in head and neck cancer.
Aapro MS; Alberts DS
Invest New Drugs; 1984; 2(3):329-30. PubMed ID: 6511239
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
Schulman P; Budman DR; Vinciguerra V; Weiselberg L; Abrams S; Degnan T
Cancer Treat Rep; 1982 Jan; 66(1):171-2. PubMed ID: 7053253
[TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone: a promising new chemotherapeutic agent.
Dalton WS; Alberts DS
Ariz Med; 1984 Feb; 41(2):96-8. PubMed ID: 6703919
[No Abstract] [Full Text] [Related]
38. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
van Oosterom AT; Fosså SD; Pizzocaro G; Bergerat JP; Bono AV; De Pauw M; Sylvester R
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1239-41. PubMed ID: 6541582
[TBL] [Abstract][Full Text] [Related]
39. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
[TBL] [Abstract][Full Text] [Related]
40. [Does chemotherapy bring real benefit to patients with inoperable bronchial epidermoid cancer?].
Depierre A
Rev Mal Respir; 1986; 3(4):169-71. PubMed ID: 3786923
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
